Advertisement

Matinas BioPharma Holdings, Inc. MTNB

Set alert

Price alert · MTNB

All alert types
1.51 USD -0.39 -20.53%

At close · Oct 30

1.42 -0.09 -5.96%

After hours · Oct 30, 6:52 PM ET

Bid
1.49 × 700
Ask
1.68 × 100
1.51 Day range 1.91
0.585 52-week range 13.08
YTD
+157.68%
1 year
+11.03%
Open
1.87
Prev close
1.90
Mkt cap
1.48M
Vol
83.00K
Avg vol
92.27K
EPS
-17.55
P/E
0.00
Div yield
0.00%
More statistics
Low
1.51
High
1.91
Forward P/E
-0.17
Beta
1.73
Short ratio
0.19
Inst. own
26.08%
Dividend
0.00
Ex-div date
50-d avg
1.38
200-d avg
6.37
1y target
0.00

2Y chart

Chart tools
Interval

Events in this range
  • Oct 31, 2024Downgrade: Maxim Group · Buy → Hold
  • Nov 13, 2024Earnings: -0.85; estimate 0; surprise —%
  • Sep 28, 2026Split: 1 for 15
Signals (91)
NameDateAgo
RSI: OversoldOct 21, 20261 week ago
MACD: Sell SignalOct 19, 20261 week ago
RSI: OversoldOct 19, 20261 week ago
RSI: OversoldAug 18, 20262 months ago
MACD: Buy SignalJul 31, 20263 months ago
RSI: OversoldJul 17, 20263 months ago
SMA: BearishJul 14, 20263 months ago
RSI: OversoldJul 14, 20263 months ago
SMA: BearishJul 13, 20263 months ago
MACD: Sell SignalJul 13, 20263 months ago
SMA: BullishJul 10, 20263 months ago
MACD: Buy SignalJul 10, 20263 months ago
SMA: BearishJun 18, 20264 months ago
MACD: Sell SignalJun 12, 20264 months ago
RSI: OverboughtMay 28, 20265 months ago
MACD: Buy SignalMay 22, 20265 months ago
SMA: BullishMay 20, 20265 months ago
SMA: BearishMay 13, 20265 months ago
MACD: Sell SignalMay 12, 20265 months ago
RSI: OverboughtMay 1, 20266 months ago
SMA: BullishApr 23, 20266 months ago
MACD: Buy SignalApr 20, 20266 months ago
SMA: BearishMar 24, 20267 months ago
SMA: BullishMar 20, 20267 months ago
SMA: BearishMar 18, 20267 months ago
SMA: BullishMar 17, 20267 months ago
SMA: BearishMar 16, 20267 months ago
RSI: OverboughtJan 23, 20269 months ago
MACD: Sell SignalJan 22, 20269 months ago
SMA: BullishJan 2, 202610 months ago
SMA: BullishJan 2, 202610 months ago
RSI: OverboughtJan 2, 202610 months ago
MACD: Buy SignalDec 4, 202511 months ago
RSI: OversoldDec 3, 202511 months ago
SMA: BearishNov 19, 202511 months ago
MACD: Sell SignalNov 19, 202511 months ago
RSI: OversoldNov 19, 202511 months ago
MACD: Buy SignalNov 18, 202511 months ago
RSI: OversoldNov 5, 202512 months ago
SMA: BearishOct 16, 20251 year ago
SMA: BullishOct 13, 20251 year ago
SMA: BearishOct 10, 20251 year ago
MACD: Sell SignalSep 2, 20251 year ago
RSI: OverboughtAug 11, 20251 year ago
SMA: BullishAug 8, 20251 year ago
MACD: Buy SignalAug 8, 20251 year ago
SMA: BearishAug 6, 20251 year ago
SMA: BullishAug 4, 20251 year ago
SMA: BearishJul 29, 20251 year ago
MACD: Sell SignalJul 17, 20251 year ago
MACD: Buy SignalJul 10, 20251 year ago
MACD: Sell SignalJun 13, 20251 year ago
RSI: OverboughtJun 11, 20251 year ago
MACD: Buy SignalJun 5, 20251 year ago
MACD: Sell SignalJun 4, 20251 year ago
RSI: OverboughtMay 16, 20251 year ago
SMA: BullishApr 22, 20251 year ago
SMA: BearishApr 21, 20251 year ago
SMA: BullishApr 17, 20251 year ago
SMA: BearishApr 16, 20251 year ago
SMA: BullishApr 14, 20251 year ago
MACD: Buy SignalApr 14, 20251 year ago
MACD: Sell SignalApr 4, 20251 year ago
MACD: Buy SignalApr 1, 20251 year ago
MACD: Sell SignalMar 31, 20251 year ago
SMA: BearishMar 25, 20251 year ago
SMA: BullishMar 21, 20251 year ago
MACD: Buy SignalMar 19, 20251 year ago
MACD: Sell SignalFeb 26, 20251 year ago
SMA: BearishFeb 25, 20251 year ago
SMA: BullishFeb 21, 20251 year ago
MACD: Buy SignalFeb 21, 20251 year ago
SMA: BearishFeb 19, 20251 year ago
MACD: Sell SignalFeb 19, 20251 year ago
MACD: Buy SignalFeb 14, 20251 year ago
SMA: BullishFeb 13, 20251 year ago
SMA: BearishFeb 12, 20251 year ago
MACD: Sell SignalFeb 12, 20251 year ago
SMA: BullishFeb 11, 20251 year ago
MACD: Buy SignalFeb 11, 20251 year ago
SMA: BearishFeb 10, 20251 year ago
SMA: BullishFeb 7, 20251 year ago
SMA: BearishJan 30, 20251 year ago
MACD: Sell SignalJan 30, 20251 year ago
MACD: Buy SignalJan 28, 20251 year ago
SMA: BullishJan 24, 20251 year ago
MACD: Sell SignalJan 16, 20251 year ago
SMA: BearishJan 15, 20251 year ago
RSI: OverboughtJan 7, 20251 year ago
MACD: Buy SignalJan 2, 20251 year ago
MACD: Sell SignalDec 20, 20241 year ago

Key statistics

Market cap
2.65M
Enterprise value
-7.89M
Trailing P/E
0.00
Forward P/E
-0.17
PEG ratio
0.00
Price / book
0.12
EPS (TTM)
-4.74
Beta
1.73
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-9.13M
Total cash
14.31M
Total debt
3.24M
Return on equity
-97.59%
Shares outstanding
5.09M
Short % of float
0.66%
50-day average
1.38
200-day average
6.37

Analyst view

Consensus: none

Price target (mean) 0.00
Ratings (0m) 2 0 buy · 2 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold2
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.78.

Earnings history

Financials — quick view

All financials
MTNB Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MTNB Net income — quarterly -1.33M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MTNB EPS — quarterly -3.15
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MTNB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 20240.00-0.85——
Aug 14, 2024Jun 1, 20240.00-1.00——
May 9, 2024Mar 1, 20240.00-1.50——
Mar 27, 2024Dec 1, 20230.00-1.50——
Nov 8, 2023Sep 1, 20230.00-1.50——
Aug 9, 2023Jun 1, 20230.00-1.50——

Upgrades / downgrades

MTNB analyst upgrades and downgrades
DateFirmActionFromTo
Oct 31, 2024Maxim GroupdownBuyHold
Jan 31, 2023HC Wainwright & Co.reit—Buy
Aug 13, 2020Aegis Capitalmain—Buy
Jan 27, 2020Piper Sandlerinit—Overweight
Jan 24, 2020SunTrust Robinson Humphreyinit—Buy
Jun 26, 2019HC Wainwright & Co.init—Buy

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MTNB — it syncs with the Stock Master app.

Insider holders

MTNB insider holders
InsiderRelationLatest transactionDateShares held
CONRAD HERBERT JDirectorStock GiftJun 21, 20220
ENDE ERIC JDirectorConversion of Exercise of derivative securityJun 17, 2021144,092
JABBOUR JEROME DChief Executive OfficerConversion of Exercise of derivative securityJun 17, 2021840,011
KUCINSKI KEITH AChief Financial OfficerPurchaseNov 24, 201994,500
LEPORE PATRICK GDirectorPurchaseMay 13, 2020400,000
MANNINO RAPHAEL JOfficerConversion of Exercise of derivative securityJun 17, 20211,457,560

Institution ownership

MTNB institution ownership
Holder% heldSharesValueReported
JTC Employer Solutions Trusteee Ltd15.23%775,000403.08KSep 29, 2024
Vanguard Group Inc3.66%186,35796.92KSep 29, 2024
Highbridge Capital Management, LLC.2.54%128,95667.07KSep 29, 2024
Sargent Investment Group, LLC1.58%80,24041.73KSep 29, 2024
Blackrock Inc.0.98%49,65025.82KSep 29, 2024
Geode Capital Management, LLC0.92%46,72924.30KSep 29, 2024

Fund ownership

MTNB fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.37%120,41262.63KSep 29, 2024
Vanguard Extended Market Index Fund1.15%58,38730.37KSep 29, 2024
Fidelity Extended Market Index Fund0.55%28,01814.57KOct 30, 2024
Fidelity Total Market Index Fund0.15%7,6523.98KOct 30, 2024
Fidelity Series Total Market Index Fund0.12%6,2983.27KOct 30, 2024
Vanguard Balanced Index Fund0.06%3,2961.71KSep 29, 2024
Advertisement